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Mitochondria require nicotinamide adenine dinucleotide (NAD+) in order to carry out the fundamental 56 
processes that fuel respiration and mediate cellular energy transduction. Mitochondrial NAD+ 57 
transporters have been identified in yeast and plants 1,2 but their very existence is controversial in 58 
mammals 3-5. Here we demonstrate that mammalian mitochondria are capable of taking up intact NAD+ 59 
and identify SLC25A51 (an essential 6,7 mitochondrial protein of previously unknown function, also known 60 
as MCART1) as a mammalian mitochondrial NAD+ transporter. Loss of SLC25A51 decreases 61 
mitochondrial but not whole-cell NAD+ content, impairs mitochondrial respiration, and blocks the uptake 62 
of NAD+ into isolated mitochondria. Conversely, overexpression of SLC25A51 or a nearly identical 63 
paralog, SLC25A52, increases mitochondrial NAD+ levels and restores NAD+ uptake into yeast 64 
mitochondria lacking endogenous NAD+ transporters. Together, these findings identify SLC25A51 as the 65 
first transporter capable of importing NAD+ into mammalian mitochondria. 66 67 
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Nicotinamide adenine dinucleotide (NAD+) is vital for the metabolic reactions that fuel all life. NAD+ 68 
functions as an electron acceptor (through hydride transfer) for hundreds of reactions, becoming reduced 69 
to NADH in the process. NADH subsequently provides reducing power throughout the cell, including to 70 
complex I of the mitochondrial electron transport chain to drive cellular respiration. Due to the 71 
requirement for NAD+ in both glycolysis and mitochondrial respiration, cells possess no sustainable 72 
means to produce ATP in the absence of NAD+. In addition to its redox roles, NAD+ is also a substrate 73 
for multiple classes of signaling enzymes including sirtuins, ADP-ribosyltransferases, and cyclic ADP-74 
ribose synthases 8. Thus, changes in NAD+ availability can influence cellular behavior even at 75 
concentrations that do not interfere directly with metabolism, whereas a complete lack of NAD+ is lethal. 76 
 77 
Despite more than 100 years of research on NAD+ 3, and intense focus on NAD+-dependent processes 78 
within the mitochondrial matrix, the question of how mammalian mitochondria obtain their NAD+ pool has 79 
never been answered. The mitochondrial NAD+ pool is distinct from that in the cytosol 4,9,10 and may be 80 
regulated independently under stress 11. Yeast and plants possess well-characterized transporters 81 
embedded in the inner mitochondrial membrane 1,2. However, no obvious homologues exist in mammals, 82 
and the most closely-related transporter has instead been characterized as a mitochondrial carrier for 83 
folate 12 and flavin adenine dinucleotide (FAD) 13. Based on the existence of a mitochondrial nicotinamide 84 
mononucleotide adenylyltransferase (NMNAT3), it has been suggested that mitochondria might take up 85 
cytosolic nicotinamide mononucleotide (NMN) and subsequently convert it to NAD+ 14. A minority of 86 
nicotinamide phosphoribosyltransferase (NAMPT) also co-purifies with liver mitochondria, leading to the 87 
alternate suggestion that mitochondria might possess an intact pathway to synthesize NAD+ directly from 88 
nicotinamide 4. However, mitochondria from multiple mammalian cell types lack active NAMPT, arguing 89 
against this as a universal mechanism 10,15-17. In addition, mice lacking NMNAT3 survive to adulthood 90 
and have no overt change in mitochondrial NAD+ content 18,19. We recently showed that isolated 91 
mitochondria do not synthesize NAD+ within the matrix from exogenous nicotinamide or NMN, but that 92 
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stable-isotope labeled NAD+ can be taken up from the cytosol 15. Thus, our data support the existence of 93 
a mammalian mitochondrial NAD+ transporter, but its molecular identity has remained a mystery. 94 
 95 
Here we identify SLC25A51 as a mammalian mitochondrial NAD+ transporter. We considered SLC25A51 96 
as a candidate because it was identified as an essential gene in several genome-wide screens 6,7 and is 97 
a member of the mitochondrial carrier family that has not previously been assigned a function (Extended 98 
Data Table 1). We show that expression of SLC25A51 dictates mitochondrial NAD+ levels and uptake 99 
capacity in mammalian cells and complements yeast lacking their known mitochondrial NAD+ 100 
transporters. A nearly identical paralog, SLC25A52, is also capable of restoring NAD+ uptake in yeast, 101 
but is not widely expressed 20. Thus, SLC25A51-dependent direct uptake is an important mechanism by 102 
which mammalian mitochondria obtain NAD+. 103 
 104 
SLC25A51 sets mitochondrial NAD+ levels 105 
To test whether SLC25A51 plays a role in mitochondrial NAD+ homeostasis, we performed knockdown 106 
experiments in human cell lines using multiple distinct shRNA and siRNA sequences. We found that 107 
SLC25A51 is required for the maintenance of mitochondrial NAD+ levels (Fig. 1a, Extended Data Fig. 1a-108 
c) but does not affect total cellular NAD+ content (Fig. 1b, Extended Data Fig. 1d). To measure 109 
mitochondrial free NAD+ concentrations in intact cells and avoid any artifacts that might be produced 110 
during isolation, we next employed two distinct mitochondrially-targeted NAD+ biosensors. The first 111 
sensor couples an engineered NAD+-binding domain with circularly-permutated Venus (cpVenus) to 112 
report local concentrations of free NAD+ via ratiometric changes in the fluorescence intensity 9. This 113 
method confirmed a decline in mitochondrial free NAD+ levels in SLC25A51-deficient tumor cells and 114 
mouse embryonic stem cells (Fig. 1c, Extended Data Fig. 1e-g). Overexpression of either SLC25A51 or 115 
its nearly identical paralog, SLC25A52, was sufficient to increase mitochondrial free NAD+ levels, similar 116 
to the effect of overexpressing the yeast mitochondrial NAD+ transporter NDT1, whereas candidates with 117 
greater homology to NDT1 had no effect (Fig. 1d, Extended Data Fig. 1h). The effects of SLC25A51 and 118 
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SLC25A52 on mitochondrial free NAD+ levels were confirmed using the FRET-based NAD+-Snifit 119 
biosensor NAD+ (Fig. 1e,f) 21. Both Flag-HA-SLC25A51 and Flag-HA-SLC25A52 co-localized with the 120 
mitochondrial marker MTC02 (Extended Data Fig. 1i). We focused primarily on SLC25A51, rather than 121 
SLC25A52 because the latter exhibits a more restricted expression pattern 20 and has not emerged as 122 
essential in screens performed to date 6,7,22,23. 123 
 124 
To understand the consequences of total SLC25A51 loss, we studied knockout (KO) cells generated by 125 
CRISPR in HAP1 cells, where SLC25A51 was previously reported to be non-essential 22. Targeted cells 126 
survived and proliferated, albeit at a reduced rate, similar to cell lines with shRNA-based knockdowns 127 
(Extended Data Fig. 1j-l). No compensatory upregulation of SLC25A52 was detected in any of the cell 128 
lines (Extended Data Fig. 1m-o), although its expression may have contributed to the survival of KO cells 129 
and may account for a residual band that was apparent when blotting for SLC25A51 (Extended Fig. 1p). 130 
SLC25A51 KO cells exhibited loss of mitochondrial NAD+ (Fig. 1g), but not total cellular NAD+ (Fig. 1h). 131 
Metabolomic profiling revealed that only NAD+, NADH and the NAD+-derived metabolite cyclic ADP-132 
ribose were significantly changed in mitochondrial extracts (Fig. 1i, Extended data Fig. 1q). In contrast, 133 
NAD+ and NADH levels were unchanged in whole cell extracts, while several sugars and nucleotide-134 
related metabolites were decreased, and hydroxyproline increased, likely reflecting a combination of 135 
impaired mitochondrial metabolism and increased reliance on glycolytic energy production (Fig. 1j, 136 
Extended data Fig. 1r). Thus, loss of SLC25A51 results in selective loss of NAD+ from the mitochondrial 137 
fraction. 138 
 139 
Loss of SLC25A51 impairs mitochondria 140 
Mitochondrial NAD+ is essential for the tricarboxylic acid cycle to fuel oxidative phosphorylation. Loss of 141 
NAMPT activity causes NAD+ deficiency and impairs mitochondrial respiration in mammalian cells and 142 
tissues 24,25. Exogenous NAD+ was sufficient to rescue respiratory capacity in mitochondria isolated from 143 
cells treated with NAMPT inhibitor FK866 (Extended Data Fig. 2a), similar to a previous report using 144 
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mitochondria isolated from cells cultured under nutrient-poor conditions 26. SLC25A51 deficiency (Fig. 2a, 145 
Extended Data Fig. 2b,c) or KO (Fig. 2b) impaired basal and maximal respiratory capacity in cells and 146 
complex I-dependent respiration in isolated mitochondria. However, exogenous NAD+ was insufficient to 147 
restore respiration in mitochondria from cells with SLC25A51 knockdown (Extended Data Fig. 2d). 148 
Adenoviral expression of SLC25A51 restored respiration in KO cells, and further increased the 149 
respiration of wild type cells when given at a low, but not a high multiplicity of infection (Fig. 2d). This is 150 
consistent with prior observations that excess NDT1/2 activity decreases mitochondrial efficiency in yeast 151 
27 and impairs respiration in mammalian cells 5. Thus, expression of SLC25A51 profoundly impacts 152 
cellular respiration. 153 
 154 
In contrast to respiratory capacity, mitochondrial membrane potential was maintained after SLC25A51 155 
loss. Staining with tetramethylrhodamine ethylester (TMRE), which accumulates in mitochondria 156 
proportionally to their membrane potential, was modestly increased in SLC25A51 KO cells (Fig. 2e). This 157 
likely reflects an increase in mitochondrial abundance, rather than membrane potential, since a similar 158 
increase in signal was noted for cells stained with MitoTracker dye (Fig. 2f). A modest increase in 159 
mitochondrial volume was confirmed by staining mitochondria in cells with shRNA-mediated depletion of 160 
SLC25A51 using anti-MTC02 antibody and performing 3D reconstructions (Fig. 2g,h Extended Data Fig. 161 
2e,f). Interestingly, SLC25A51 is reported to interact with C7orf55, an assembly factor for complex V of 162 
the electron transport chain, and Bola1, a protein that forms an iron-sulfur linked complex with 163 
glutaredoxin 5 and may be involved in oxidative stress resistance 28. We detected no apparent change in 164 
the expression of the complex V subunit ATP5A (Fig. 2i) and note that uncoupling (bypassing complex V) 165 
did not restore respiration in SLC25A51 deficient cells (Fig. 2a,b, Extended Fig. 2b). However, 166 
expression of complex I, II, and IV subunits was reduced (Fig 2i), and we cannot rule out a contribution of 167 
changes in iron-sulfur cluster metabolism or oxidative stress to the observed effects of SLC25A51 168 
deficiency.  169 
 170 
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SLC25A51 drives mitochondrial NAD+ uptake 171 
To test whether SLC25A51 mediates uptake of NAD+ into mammalian mitochondria, we isolated 172 
organelles from SLC25A51-depleted and SLC25A51 KO cells and incubated with exogenous NAD+. 173 
Exogenous NAD+ increased the matrix NAD+ content in control mitochondria or in mitochondria that had 174 
low NAD+ content due to inhibition of NAD+ synthesis with FK866 in the parent cells (Fig. 3a,b, Extended 175 
Data Fig. 3a). This effect was specific to NAD+, as it was not recapitulated with either nicotinamide or 176 
NMN (Extended Data Fig. 3b). Moreover, addition of excess nicotinamide or NMN failed to compete with 177 
uptake of NAD+ (Extended Data Fig. 3c). In mitochondria isolated from SLC25A51 deficient cells, 178 
exogenous NAD+ did not increase the matrix NAD+ content (Fig. 3a,b). Further, re-expression of 179 
SLC25A51 in depleted or KO cells restored uptake of exogenous NAD+ (Fig. 3a,b). Yeast NDT1, a bona 180 
fide mitochondrial NAD+ transporter 2, similarly rescued NAD+ uptake in SLC25A51 deficient cells (Fig. 181 
3c). This indicates that a lack of transport activity is likely the defect limiting mitochondrial NAD+ 182 
accumulation in the absence of SLC25A51. Consistent with a direct role for SLC25A51 in NAD+ transport, 183 
overexpression was sufficient to increase uptake of exogenous NAD+ into isolated mitochondria (Fig. 3d). 184 
Finally, we used a mitochondrially-targeted biosensor in intact cells to show that incubation with the 185 
NAD+ precursor nicotinamide riboside (NR) was sufficient to restore mitochondrial NAD+ levels in an 186 
SLC25A51-dependent manner (Fig. 3e). Together, these data indicate that the ability of mitochondria to 187 
import NAD+ is dependent on the expression of either SLC25A51 or a protein with NAD+ transporter 188 
activity.  189 
 190 
To further investigate the capabilities of SLC25A51 and SLC25A52 to mediate mitochondrial NAD+ 191 
transport in intact cells, we employed a mitochondrially-targeted poly ADP-ribose polymerase 192 
(mitoPARPcd) 29. This reporter system is based on the continuous consumption of mitochondrial NAD+ 193 
and its preference for automodification with poly ADP-ribose (PAR). Thus, the steady-state level of PAR 194 
is an indication of the ability of mitochondria to replenish the NAD+ pool.  Overexpression of SLC25A51 195 
or SLC25A52 dramatically enhanced the signal of the mitoPARPcd reporter, similar to the effect of the 196 
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Arabidopsis thaliana NAD+ transporter AtNDT2 (Fig. 3f,g).  Expression of SLC25A32, the mammalian 197 
mitochondrial carrier most homologous to AtNDT2, had no effect as reported previously 5. 198 
 199 
Nicotinic acid riboside (NaR) is converted to NAD+ via the cytosolic enzyme NAD+ synthase. By 200 
isotopically labeling both the nicotinic acid and ribose moieties, we can monitor a pool of NAD+ 201 
synthesized in the cytosol, which we previously demonstrated is able to enter the mitochondria 15. We 202 
incubated wild type and SLC25A51 KO HAP1 cells with double-labeled NaR and measured the 203 
appearance of double-labeled NAD+ in the mitochondria. While NaR increased the total abundance of 204 
mitochondrial NAD+ in wild type cells, it had no effect in SLC25A51 KO cells (Fig. 3h). Whole cell NAD+ 205 
pools were labeled to a similar extent in both cell populations (Fig. 3i), but as expected, a substantial 206 
portion of the labeled NAD+ entered the mitochondria only in wild type cells and not in the SLC25A51 KO 207 
cells (Fig. 3j). Notably the small amount of NAD+ that was present in the KO cells still partially labeled, 208 
suggesting that even the residual NAD+ is taken up directly, whether via SLC25A52 or another 209 
mechanism, and not synthesized within the mitochondria (Extended Data Fig. 3d).   210 
 211 
SLC25A51 complements NDT1/2 deficiency 212 
To explore the function of SLC25A51 in a system that lacks transport activity, we developed a 213 
recombinant assay using 3H-NAD+ in yeast deleted for the genes encoding both established 214 
mitochondrial NAD+ transporters, NDT1 and NDT2 (DKO) (Extended Data Fig. 4a-e). We isolated 215 
mitochondria from either wildtype or DKO yeast in mid-exponential growth and incubated with 100 µM 216 
NAD+ (3H-NAD+ traced). Wildtype mitochondria readily imported NAD+, with an initial rate of 7.6 ± 1.5 217 
pmol/min (Fig. 4a-c, Extended Data Table 2). There was minimal uptake of NAD+ by DKO mitochondria 218 
over 30 minutes. Ectopic expression of human SLC25A51 in the DKO strain fully rescued mitochondrial 219 
NAD+ uptake (initial rate 12.1 ± 2.8 pmol/min), and SLC25A52 provided a partial rescue (initial rate 4.3 ± 220 
1.5 pmol/min) (Fig. 4a-c, Extended Data Table 2). As expected, excess unlabeled NAD+ competed with 221 
import of 3H-NAD+ into DKO cells rescued with SLC25A51 (Extended Data Fig. 5a). On the other hand, 222 
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the initial rate of uptake was not significantly altered by up to 500 µM NMN or 100 µM NADH (Extended 223 
Fig. 5b,c, Extended Data Table 2), supraphysiological concentrations exceeding free cytosolic levels by 224 
1-2 orders of magnitude 21,30-32. Consistent with the ability of human SLC25A51 and SLC25A52 to 225 
transport NAD+ into mitochondria, expression of either in the DKO strain was sufficient to restore 226 
mitochondrial NAD+ levels (Fig. 4d). While proof that reconstituted SLC25A51 is sufficient to transport 227 
NAD+ in an isolated system is still lacking, these experiments demonstrate that it can functionally replace 228 
bona fide mitochondrial NAD+ transporters. To define kinetic parameters for SLC25A51, we determined 229 
the abundance of SLC25A51 in mitochondrial preparations. We obtained mass spectrometry data for 15 230 
mitochondrial proteins of similar molecular weights whose levels did not fluctuate across experimental 231 
conditions. Peptide counts were mapped onto a meta-dataset of absolute yeast protein abundances 33 to 232 
obtain a standard curve that was then used to estimate the concentration of SLC25A51 in each sample 233 
(Extended Data Fig. 5d), yielding a value of approximately 475 ng (~14 pmol) of SLC25A51 per milligram 234 
of isolated mitochondria. We measured NAD+ uptake by SLC25A51 at 1 minute, 3 minutes, and 30 235 
minutes using a range of NAD+ concentrations, 100 µM, 200 µM, 300 µM, 500 µM, and 1000 µM NAD+ 236 
(Extended Fig. 5e). Initial rates were interpolated from the linear portions of the curves between 0.1 - 0.2 237 
minutes. We plotted mean initial rates against NAD+ concentrations in a double reciprocal (Lineweaver-238 
Burk) plot and used the Michaelis-Menten equation to determine a KM, apparent (NAD
+) for SLC25A51 of ~ 239 
200 µM ± 60 µM and its Vmax, apparent approximated 1200 pmol sec
-1 mg-1 ± 300 pmol sec-1 (Extended Data 240 
Fig. 5f). Together, these data demonstrate that human SLC25A51 and human SLC25A52 can directly 241 
transport NAD+ into the mitochondrial matrix. 242 
 243 
Conclusion 244 
Despite the central role of NAD+ in mitochondrial metabolism, the mechanism by which mammalian 245 
organelles obtain this dinucleotide has never been elucidated 9,15. Here we have shown that SLC25A51 246 
and its paralog, SLC25A52, are both capable of mediating mitochondrial uptake of NAD+, and that 247 
SLC25A51 is required for the maintenance of normal mitochondrial NAD+ levels in human cells. While 248 
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these data do not exclude the possibility that other modes of mitochondrial NAD+ replenishment exist, the 249 
essential nature of SLC25A51 across multiple cell lines suggest that direct SLC25A51-mediated uptake 250 
is a major mechanism responsible for the generation of the mitochondrial NAD+ pool in mammals. 251 
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Figure Legends  356 
Figure 1. SLC25A51 and SLC25A52 expression dictates mitochondrial NAD+ concentration. 357 
a, NAD+ content of isolated mitochondria (n=4) and b, whole cell lysates (n=3) from HEK293T cells 358 
stably depleted of SLC25A51 (shRNA1-3) and stably expressing non-targeting control shRNA (Ctrl). c, 359 
Mitochondrial free NAD+ levels in HeLa cells transfected with siRNA targeting SLC25A51 (siRNA1 and 2) 360 
and non-targeting siRNA (Ctrl), measured by the mitochondrially-targeted cpVenus NAD+ biosensor, 361 
(n=4). d, Mitochondrial free NAD+ levels in HeLa cells overexpressing NDT1 (yeast mitochondrial NAD+ 362 
transporter) (n=24), SLC25A32 (n=4), SLC25A33 (n=4), SLC25A36 (n=4), SLC25A51 (n=4), SLC25A52 363 
(n=4), and vector control (n=24) measured by the cpVenus NAD+ biosensor. e, Mitochondrial free NAD+ 364 
levels in HEK293 cells with stable shRNA-mediated knockdown of SLC25A51 (n=3) and stable 365 
expression of non-targeting shRNA (Ctrl) (n=3). f, Mitochondrial free NAD+ levels in U2OS cells 366 
overexpressing SLC25A51, SLC25A52 and vector control (n=6), as measured by NAD+-Snifit. g, 367 
Mitochondrial (n=3) and h, whole cell NAD+ content (n=3) of lysates collected from CRISPR/Cas9-368 
mediated SLC25A51 knockout (KO) and wildtype (WT) HAP1 cells. i, Mitochondrial (n=3) and j, whole 369 
cell (n=3) metabolomes of HAP1 SLC25A51 KO and WT cells measured by liquid chromatography–mass 370 
spectrometry. Significantly changed metabolites were determined by setting a false discovery rate of 1% 371 
(two-stage step-up method of Benjamini, Krieger, and Yekutieli) and are represented in a volcano plot. n 372 
represents biological independent replicates. Data represented as mean ± SEM. P values were 373 
determined by unpaired, two-tailed Student’s t-test (for two groups) or one-way ANOVA with multiple 374 
comparisons analysis using Dunnett’s method (for groups of three or more). **P<0.01, ***P<0.001 vs. 375 
control, vector, or wildtype (exact P values are provided in the source data). 376 
 377 
Figure 2. SLC25A51 modulates mitochondrial respiratory capacity. 378 
Oxygen consumption rate (OCR) for a, SLC25A51 shRNA-depleted HEK293T (n=5), b, HAP1 379 
SLC25A51 KO cells (n=6), c, HAP1 SLC25A51 KO cells rescued using adenovirus-mediated SLC25A51 380 
expression (multiplicity of infection or MOI-4) (n=6), and d, HAP1 wildtype cells with low (MOI-2), 381 
medium (MOI-4) and high (MOI-6) overexpression of SLC25A51 (n=6) (80,000 cells per well). Basal 382 
OCR was measured prior to the addition of treatments and maximal respiration was measured after the 383 
sequential addition of oligomycin (Oligo, ATP synthase inhibitor) and FCCP (uncoupler). Rotenone (Rot) 384 
and Antimycin A (AA) were then added as a control to completely block mitochondrial oxygen 385 
consumption. e, Quantification of mitochondrial membrane potential using the cell permeant fluorescent 386 
dye tetramethylrhodamine, ethyl ester (TMRE) (n=4). f, Mitochondrial content measured by fluorescence 387 
intensity of the mitochondrial localization dye, MitoTracker Deep Red (n=4). Relative fluorescence 388 
intensities were determined by flow cytometry. g, Cumulative mitochondrial volume per cell quantified 389 
from confocal image reconstructions of mitochondrial voxels in SLC25A51 shRNA knockdown (n=31 390 
cells) and control (n=32 cells) HeLa cells. h, Representative images of mitochondrial voxels 391 
(mitochondrial marker, anti-MTC02) reconstructed using 0.1 µm optical slices and Imaris Surface 392 
Analyses. Scale bar: top, 5 µm; bottom, 1 µm. i, Western blot of mitochondrial oxidative phosphorylation 393 
complexes in HAP1 SLC25A51 KO cells. TOM20 was blotted as a mitochondrial loading control. n 394 
represents biological independent replicates unless otherwise indicated. Data represented as mean ± 395 
SEM. P values were determined by unpaired, two-tailed Student’s t-test or two-way ANOVA with multiple 396 
comparisons analysis using Dunnett’s method (for groups of three or more). *P<0.05, **P<0.01, and 397 
***P<0.001 vs. control, wildtype, or KO (exact P values are provided in the source data). 398 
 399 
Figure 3. SLC25A51 expression is required for NAD+ uptake in isolated mitochondria.  400 
NAD+ content of isolated mitochondria measured before and after a 40-min incubation with 1 mM NAD+ 401 
from a, HEK293T control (Ctrl) cells, control + FK866 (Ctrl+FK) to deplete mitochondrial NAD+, 402 
SLC25A51 shRNA knockdown (KD) cells, and SLC25A51 KD + murine Slc25a51 cDNA (KD+A51) cells; 403 
b, HAP1 wildtype (WT) cells, WT + FK866 (WT+FK), SLC25A51 (KO) knockout cells, and KO cells 404 
transduced with adenovirus encoding SLC25A51 (KO+A51); and c, HEK293T control (Ctrl) cells, control 405 
+FK866 (Ctrl+FK), SLC25A51 (KD) cells, and SLC25A51 KD cells + cDNA encoding the yeast 406 
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mitochondrial NAD+ transporter NDT1 (KD+NDT1). d, NAD+ content of mitochondria isolated from 407 
HEK293T control cells and cells overexpressing SLC25A51 (OE) before and after a 20-min incubation 408 
with 1 mM NAD+ (a-d; n=3 independent experiments). e, HeLa cells were transfected 3 days in advance 409 
with non-targeting siRNA (siNT) and siRNA targeting SLC25A51 (siA51), or NAMPT (siNampt) and 410 
mitochondrial free NAD+ levels were measured after 16-hours of nicotinamide riboside (NR) treatment 411 
(n=3). f, HEK293 cells stably expressing Arabidopsis thaliana NDT2-FLAG (AtNDT2), SLC25A32-FLAG, 412 
SLC25A51-FLAG or g, SLC25A52-FLAG were transfected with mitochondrially-targeted eGFP (mito-413 
eGFP) or the catalytic domain of PARP1 (mitoPARP1cd). Mitochondrial PARylation levels reflect 414 
mitochondrial NAD+ availability. h, Mitochondrial NAD+ content after 7-hours of treatment with doubly 415 
isotopically labeled nicotinic acid riboside (NaR). i, Whole cell and j, mitochondrial fractional labeling 416 
patterns normalized to total ion counts in WT to reflect relative abundance of NAD+ after NaR treatment 417 
(n=3). n represents biological independent replicates unless otherwise indicated. Data represented as 418 
mean ± SEM. P values were determined by unpaired, two-tailed Student’s t-test. *P<0.05, **P<0.01, and 419 
***P<0.001 vs untreated, wildtype M+0; ###P<0.001 vs control + NAD+, wildtype M+1; ^^^P<0.001 vs 420 
wildtype M+2 (exact P values are provided in the source data). 421 
 422 
Figure 4. SLC25A51 is sufficient for transport of NAD+ into yeast mitochondria lacking their 423 
endogenous transporters, NDT1 and NDT2. 424 
3H-NAD+ uptake measured in isolated mitochondria from wildtype (n=4 independent experiments), NDT1 425 
and NDT2 double knockout (DKO) (n=4 independent experiments), and a, DKO + overexpression of 426 
SLC25A51 (n=4 independent experiments) or b, DKO + overexpression of SLC25A52 (n=3 independent 427 
experiments) yeast; grey line indicates mean basal radioactivity in DKO samples. P values were 428 
determined by a two-way ANOVA with multiple comparisons analysis using Dunnett’s method. c, Initial 429 
rates of NAD+ uptake into isolated yeast mitochondria (n=4 independent experiments for WT, DKO, and 430 
DKO + SLC25A51; n=3 for DKO + SLC25A52). d, NAD+ content measured from isolated yeast 431 
mitochondria (n=3 biological independent replicates). P values were determined by one-way ANOVA 432 
with multiple comparisons analysis using Tukey’s method. Data represented as mean ± SEM. **P<0.01, 433 
and ***P<0.001 vs DKO, ##P<0.01 and ###P<0.001 vs wildtype (exact P values are provided in the source 434 
data).  435 




Cell Culture 440 
HEK293T (ATCC: CRL-3216), HEK293 (ATCC: CRL-1573), HeLa (ATCC: CCL-2), U2OS (ECACC: 441 
92022711) cells were cultured in either Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5 g/L 442 
glucose, 1 mM sodium pyruvate and 4 mM L-glutamine with supplemented with 10% fetal bovine serum 443 
and 1x penicillin/streptomycin, or a custom DMEM formulation without antibiotics or niacinamide for 444 
nicotinamide riboside (NR) (3-(aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium, CAS Number 1341-23-7) 445 
supplementation assays. HAP1 wildtype (Horizon Discovery: C631) and HAP1 SLC25A51 knockout 4bp 446 
deletion (Horizon Discovery: HZGHC001927c010) cells were cultured in Iscove's Modified Dulbecco's 447 
culture medium supplemented with 10% fetal bovine serum and 1x penicillin/streptomycin. Low-passage 448 
J1 murine embryonic stem cells (ATCC: SCRC-1010) were cultured in DMEM containing 4.5g/L glucose 449 
without pyruvate (Sigma #D5796), 20% fetal bovine serum (Sigma #12306C), 1X EmbryoMax 450 
Nucleoside Mix (Millipore #ES-008D), 1X Non-Essential Amino Acids Mix (Millipore #MS-001-C), 100 µM 451 
beta-mercaptoethanol (Sigma #M3148), and 7 x 106 U recombinant murine LIF (Millipore #ESG1107). 452 
Cells were grown at 37°C with 5% CO2. After stable depletion or deletion of SLC25A51, medium was 453 
supplemented with 50 µg/mL uridine (1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-454 
yl]pyrimidine-2,4-dione, CAS Number :  58-96-8) to improve cellular viability. To deplete NAD+, cells were 455 
treated with 100 nM FK866 (N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2E-propenamide, CAS 456 
Number: 658084-64-1) for 18-24 hours. 457 
 458 
Generation of NAD+ sensor cell lines 459 
Clonal HeLa mitocpVenus and HeLa mitoSensor cell lines were generated by lentiviral transduction 460 
of HeLa cells (ATCC: CCL-2) with virus encoding mitocpVenus or mitoSensor at a MOI of approximately 461 
one. Stable integration was selected with 2.5 µg/mL puromycin ((2S)-2-amino-N-[(2S,3S,4R,5R)-5-[6-462 
(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide, 463 
CAS Number 58-58-2)  for two weeks and individual clones were then isolated by dilution plating. Once 464 
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colonies were established, 10 clonal lines were screened to confirm fluorescence and responses to 465 
FK866 treatment (10 nM, 16 hours).  466 
A U2OS and HEK293 FlpIn T-Rex cell lines were generated as described previously 34. The Flp-467 
In T-Rex System (ThermoFisher Scientific) was used to generate inducible U2OS and HEK293 Flp-468 
In cell lines that express the NAD+ Snifit in the mitochondria. pcDNA5-FRT-Cox8-SPR-Halo-p30-469 
SNAP19 and the Flp recombinase (pOG44) were co-transfected into the host FlpIn cell line following the 470 
manufacturer’s instructions. Homologous recombination between the FRT sites in pcDNA5-FRT-Cox8-471 
SPR-Halo-p30-SNAP and the host cell chromosome, catalysed by the Flp recombinase expressed from 472 
pOG44, produced stable and inducible U2OS and HEK293 FlpIn cells. Cells were single-cell sorted 473 
before usage.  474 
 475 
shRNA and siRNA knockdown 476 
Cells were transduced with lentivirus encoding shRNA targeting against human SLC25A51 (Sigma, 477 







Non-targeting control shGFP targeting sequence: GCAAGCTGACCCTGAAGTTCAT3 485 
To generate stable knockdown cell lines, cells were selected with 2 µg/mL puromycin. Both gene 486 
expression and mitochondrial NAD+ levels were used to validate targeting sequences (shRNA1-sh234), 487 
(shRNA2-sh235), and (shRNA3-sh237).  For human cell lines, TRCN0000060235 was used in figures 488 
simply referencing knockdown (KD). All of the analyses were conducted before the 5th passage after 489 
transduction. 490 
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Murine shRNA against Slc25a51: 491 
To transiently deplete SLC25A51 expression and measure mitochondrial free NAD+, J1 mouse 492 
embryonic stem cells were co-transfected using linear polyethylenimine (MW 250,000) with plasmids 493 
encoding shRNA targeting murine Slc25a51 and either mitocpVenus-IRES-puromycinR or mitoSensor-494 
IRES-puromycinR expressed from an EF1α promoter. Plasmids were transfected at a ratio of 3:1 495 
shRNA:sensor. The shRNA or control shFF2 (targeting firefly luciferase) hairpins were flanked by 496 
microRNA-30 sequences and constitutively expressed via the UBC promoter from the 3’UTR of a 497 
puromycin-resistance cassette. Two days post-transfection, cells were selected with 1 µg/mL puromycin 498 
for an additional 48 hours. 499 
Murine Slc25a51 hairpin:  500 
GGTATATTGCTGTTGACAGTGAGCGAGGCCTTCGAGGGCCCATTAAGGTAGTGAAGCCACAGATGT501 
ACCTTAATGGGCCCTCGAAGGCATGCCTACTGCCTCGGACTTC 502 
Non-targeting control shFF2 (firefly luciferase #2) hairpin: 503 
GGTATATTGCTGTTGACAGTGAGCGAUGGUCCAACCGACUAAUACAGTAGTGAAGCCACAGATGTA504 
CTGTATTAGTCGGTTGGACCAATGCCTACTGCCTCGGACTTC 505 
siRNA knockdown: 506 
siGENOME siRNAs targeting human SLC25A51 (D-007358-01, D-007358-02), NAMPT (D-004581-01) 507 
and Non-Targeting Scramble controls (D-001206-14) were obtained from Dharmacon RNAi 508 
Technologies and resuspended at 20 µM in 10mM Tris pH 8.0 buffer. Lipofectamine RNAiMax 509 
transfection reagent (ThermoFisher Scientific) was used to transfect siRNA into cells. Cells were grown 510 
in DMEM complete media and incubated for 72 hours after treatment. 511 
 512 
Expression plasmids 513 
Human cDNA encoding SLC25A51 (NCBI: NM_033412) and SLC25A52 (NCBI: NM_001034172) were 514 
either purchased from Origene (SLC25A51: RC203348 or MR204144; SLC25A52: RC215808) or 515 
synthesized as double-stranded DNA fragments. Synthesized sequences are either codon-optimized for 516 
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expression in S. cerevisiae or mammals. cDNA encoding NDT1 was obtained with gene-specific PCR 517 
from genomic DNA of BY4742 and expressed from its endogenous promoter.  These genes were either 518 
cloned into pRS415 with HiFi assembly, or into pENTR-D-Topo (Gateway System, ThermoFisher 519 
Scientific). pENTR constructs were recombined using LR Clonase II into mammalian expression vectors. 520 
 521 
Analysis of gene expression 522 
RNA was isolated using the Qiagen RNeasy Mini Kit (Qiagen, #74104) and cDNA was generated using 523 
the Applied Biosystems High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, #4368814). 524 
qPCR analysis was conducted following the manufacturer’s instructions (Power Sybr, ThermoFisher 525 
Scientific #4367659). Human 18S was used as a house keeping control. To calculate fold change in 526 
mRNA expression, the 2−∆∆Ct method was used. Primers: yeast-codon optimized SLC25A51 (Fwd: 527 
ATAGGTGGCGAGTTTCAGAGTTT, Rev: TGAACGGTGATAGTTTAGGTGGG); yeast codon-optimized 528 
SLC25A52 (Fwd: CCATCACCTATCCGATCCAGAAG, Rev: TGGTGGCAGAATTCCTCTGTAAA);  529 
endogenous human SLC25A51 mRNA (Fwd: TACCAACACTTACCAGGCTTTCA, Rev: 530 
CAAGACATTGCTGAGTCCATTCC OR Fwd: CGCTGATGGGAAATCCAGTTA, Rev: 531 
CTGGAGTTTGGCAGGATGATAG); human SLC25A52 mRNA (Fwd: ATGGACTCGGGAAGAGAGAA, 532 
Rev: CTGGAGTTTGGCAGGATGATAG); human 18S mRNA (Fwd: TTGACGGAAGGGCACCACCAG, 533 
Rev: GCACCACCACCCACGGAATCG). 534 
 535 
Lysis and Western Blotting 536 
Cells were washed with ice-cold PBS and lysed directly in either RIPA buffer (Cell Signaling: #9806) with 537 
Halt Protease and Phosphatase Inhibitor (ThermoScientific, #78442) or 2X Laemmli sample buffer 538 
containing DTT. Protein samples were electrophoresed on 4-12% Bis-Tris protein gels (Invitrogen) or 539 
10% Mini-PROTEAN TGX precast gel (BioRad) and transferred to 0.45 μm nitrocellulose or PVDF 540 
membrane (Bio-Rad). Membranes were blocked with 5% BSA or 5% milk in Tris-buffered saline (TBS) 541 
pH 7.6 containing 0.1% (v/v) Tween 20 (TBST) or LiCOR blocking buffer. Antibodies were prepared in 542 
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1% BSA or 1:1 LiCOR Blocking Buffer in TBST. Dilutions were as follows: anti-SLC25A51 (ProSci, #55-543 
424, 1:200), anti-Flag M2 (Sigma, #F1804, 1:3,000), anti-α-Tubulin (Sigma, #T9026, 1:3,000), anti-Total 544 
OXPHOS (Abcam, #ab110413, 1:2,000), anti-TOM20 (Santa Cruz Biotechnology, #sc-17764),  anti-PAR 545 
10H (Enzo, #LX-804-220-R100, 1:6,000), anti-GFP JL-8 (Takara Clontech, #632381, 1:15,000), anti-SC2 546 
(Novus Bio, #NBP1-92465, 1:1,000), anti-Actin (Abcam, #ab14128, 1:1000), anti-MTC02 (Abcam, 547 
#ab9479, 1:1000), anti-CoxIV (Abcam, #ab33985, 1:1000), anit-β-tubulin (Sigma, #T5293, 1:10,000) and 548 
anti-mouse IgG H&L IRDye® 800CW (Abcam, #ab216773, 1:10,000), IRDye® 680RD Goat anti-Mouse 549 
IgG (LiCOR, #926-68070, 1:12,000), IRDye® 800CW Donkey anti-Rabbit IgG (LiCOR, #926-32213, 550 
1:12,000). Total protein loading was determined using Revert 700 Total Protein Dye (LiCOR, #926-551 
11010). Membranes were imaged using a LiCOR Odyssey Clx or a ChemiDoc XRS+ imaging system 552 
(Bio-Rad).  553 
 554 
Overexpression of SLC25A51 555 
SLC25A51 was cloned into pAd/CMV/V5-dest (Invitrogen, V49320) from the entry plasmid Gateway 556 
PLUS shuttle clone for SLC25A51 (NM_033412.3) (Genecopoeia, #GC-T0831) by recombination using 557 
LR Clonase II (Gateway system; Invitrogen, #11791020. pAd/CMV/V5-dest containing SLC25A51 was 558 
used to generate adenovirus in HEK293T cells. Adenovirus titer was determined, and cells were treated 559 
with adenovirus encoding SLC25A51 at a multiplicity of infection (MOI) ranging from 2-6. 16-20 hrs after 560 
transduction, the virus-containing medium was removed, and new medium was added. To restore 561 
SLC25A51 expression in SLC25A51 knockdown cells, a plasmid encoding murine Slc25a51 was 562 
transfected into cells using Fugene 6 (1:3 DNA:Fugene ratio) (Promega, #E269A). Cells were transfected 563 
or transduced 48-72 hours prior to the experiment. A stable SLC25A51 overexpression cell line was 564 
generated using genomic integration with lentivirus encoding SLC25A51 in HEK293T cells. After 565 
transduction, the cell line was selected using puromycin as described above. 566 
 567 
NAD+ measurement in extracts 568 
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Cells and mitochondria were extracted with ice-cold 0.6 N perchloric acid. NAD+ was measured after 569 
extraction by an enzymatic cycling assay in a 96-well format. Standards or diluted sample extracts  (at 570 
least 1:10 in in 100 mM phosphate buffer, pH 8.0) were combined with 95 μl of cycling mixture (2% 571 
ethanol, 100 μg/mL alcohol dehydrogenase, 10 μg/mL diaphorase, 20 μM resazurin, 10 μM flavin 572 
mononucleotide, 10 mM nicotinamide, 0.1% BSA in 100 mM phosphate buffer, pH 8.0). The rate of 573 
resorufin accumulation was measured by comparing fluorescence excitation at 544 nm and emission at 574 
590 nm before and after incubation of the cycling reaction for 15 minutes at room temperature. 575 
 576 
Mitochondrial NAD+ measurements using the NAD+ biosensor and semisynthetic NAD+-Snifit 577 
Clonal Hela lines stably expressing mitocpVenus or MitoSensor were seeded into a 24-well plate 578 
one day before transfection (~20,000-50,000 cells/well). The cells were transfected with mitochondrial 579 
carrier family constructs, (plasmids encoding NDT1, SLC25A32, SLC25A33, SLC25A36, SLC25A51, or 580 
SLC25A52) (0.5 μg DNA/well), using 2.5 μL of polyethylenimine solution (1 mg/mL) in 100 μL of Opti-581 
MEM or transfected with 20nM siRNA,1 μL Lipofectamine RNAiMax in 100 µL Opti-MEM. Cells were 582 
grown in DMEM complete media and incubated for 48-72 hours. For nicotinamide riboside (NR) 583 
treatment, cells were treated with 100 μM NR in complete DMEM without nicotinamide 16 hours prior to 584 
analysis. Measurements of mitochondrial NAD+ using the NAD+ biosensor has been previously described 585 
35. Briefly, HeLa mitocpVenus and HeLa mitoSensor cells were harvested in ice-cold DMEM and kept cold 586 
until analysis. Data was collected on a NovoCyte flow cytometer using the following parameters: ex. 488 587 
nm, em. 530±30 nm and ex. 405 nm, em. 530±30 nm. Cells were gated to exclude debris, a standard 588 
doublet-exclusion was performed, and 10,000 fluorescent cells were analyzed per condition. Ratiometric 589 
488/405 nm fluorescence values were obtained for each cell using the derived function on FlowJo v10.  590 
U2OS and HEK293 T-Rex Flp-In cells with an inducible NAD+-Snifit sensor in the mitochondria 591 
were plated at 5x104 cells/mL in a 24-well plate (TPP, #92024). Sensor expression was induced by the 592 
addition of doxycycline (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-593 
methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide, Cas Number 564-25-0) 594 
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(200 ng/mL). After 24 h, the cells were transfected with either cDNA encoding SLC25A51, SLC25A52 or 595 
an empty pcDNA3.1 vector using Fugene 6 (1:1.5 DNA:Fugene ratio, 0.5 μg DNA/well) Promega, 596 
#E269A). At 48 h, the cells were labelled with CP-TMR-C6-SMX (500 nM) and Halo-SiR (200 nM) 21 for 597 
16 h. The cells were resuspended in 2% FBS in PBS, filtered and subjected to flow cytometry analysis. 598 
Flow cytometry data were recorded on a FACS Melody (BD Bioscience) or an LSR II (BD Bioscience) 599 
using the following settings: TMR (ex. 561 nm, em. 582±15 nm), FRET (ex. 561 nm, em. 697±58 nm) 600 
and SiR (ex. 640 nm, em. 660±10 nm). Cells were gated to exclude debris, a standard doublet-exclusion 601 
was performed, and 10,000 fluorescent cells were analyzed per condition. The data were analyzed with 602 
FlowJo v10 software. 603 
  604 
Respiration Assays 605 
Cells (80,000 cell/well) were plated into a well of a Seahorse XF 96 well culture plate and cultured 606 
overnight.  After 16-20 hours the cells media was changed to XF DMEM Medium containing 10 mM 607 
glucose, 1 mM sodium pyruvate and 2 mM L-glutamine and incubated for 1 hour at 37°C without CO2.  608 
Cell respiration was measured using a Seahorse XF96e Analyzer.  Cells were treated with 1.5 μM 609 
oligomycin (an ATP synthase inhibitor, 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-610 
5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-611 
oxane]-13,17,23-trione, CAS Number 579-13-5), 1.5 μM FCCP (a mitochondrial uncoupler, 2-[2-[4-612 
(trifluoromethoxy)phenyl]hydrazinylidene]-propanedinitrile, CAS Number 370-86-5), 0.5 μM 613 
Rotenone/Antimycin A (Complex I and III inhibitors, Rotenone: (1S,6R,13S)-16,17-dimethoxy-6-prop-1-614 
en-2-yl-2,7,20-trioxapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-3(11),4(8),9,14,16,18-hexaen-12-one. 615 
CAS Number: 83-79-4; Antimycin A: [(2R,3S,6S,7R,8R)-3-[(3-Formamido-2-hydroxybenzoyl)amino]-8-616 
hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] 3-methylbutanoate, CAS Number: 1397-94-0). Basal 617 
respiration is respiration before the addition of any drugs and maximum respiration is peak respiration 618 
after oligomycin and FCCP treatment. 619 
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 To measure mitochondrial respiration, 7.5 μg/well mitochondria were plated on Seahorse XF 96 620 
well culture plate by centrifuging for 20 min at 1,000g. Respiration of mitochondria was measured in 621 
MiRO5 respiration medium (110 mM sucrose, 20 mM HEPES, 10 mM KH2PO4, 20 mM taurine, 60 mM K-622 
lactobionate, 3 mM MgCl2, 0.5 mM EGTA, and 1 g/L fatty acid free BSA adjust pH to 7.2 with KOH) using 623 
a Seahorse XF96e Analyzer at 37°C. To measure state 2 respiration 5 mM malate and 10 mM pyruvate 624 
were added. State 3 respiration was measured with the addition of 2 mM ADP. To inhibit complex V and 625 
block ATP generation, 1.5 μM oligomycin was added. 626 
For assessing the consequences of NAD+ depletion in mitochondria, respiration of isolated 627 
mitochondria (200 μg/chamber for Oroboros or 7.5 μg/well for Seahorse XF96e) was measured in 628 
MiRO5 respiration medium using an Oroboros high-resolution respirometer or Seahorse XF96e Analyzer 629 
at 37°C. To measure state 2 respiration 5 mM malate and 10 mM pyruvate were added. State 3 630 
respiration was measured with the addition of 2 mM ADP. After stabilization of the state 3 reading, 1 mM 631 
NAD+ was added to determine whether its addition could restore state 3 respiration in NAD+ depleted 632 
mitochondria.  633 
 634 
Cell proliferation Assay 635 
To measure cell proliferation, cells were plated at 10,000 cells per well into a 96-well plate. The CyQuant 636 
(Invitrogen, #C7026) cell proliferation assay was conducted using the manufacturer’s protocol to 637 
measure DNA content at 0 h and 96 h after plating the cells. 638 
 639 
Mitochondrial membrane potential and mitochondrial content assays: 640 
Cells were loaded with either tetramethylrhodamine, ethyl ester (TMRE) (Invitrogen: #T669) to measure 641 
mitochondrial membrane potential or MitoTracker Deep Red (Cell Signaling: #8778S) to label 642 
mitochondria following the manufacturer’s protocols. After loading, the cells were collected by 643 
trypsinization, resuspended in 2% FBS in PBS, filtered and subjected to flow cytometry analysis. Flow 644 
cytometry data were recorded on an LSR II (BD Bioscience) for 10,000 events. To measure 645 
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mitochondrial membrane potential, fluorescence intensity data was collected using ex. 561 nm, em. 646 
582±15 nm. To control for TMRE loading, FCCP was added to collapse the mitochondrial membrane 647 
potential after collecting the baseline recording. The FCCP recording was subtracted from the baseline 648 
recording. To measure mitochondrial content in intact cells, the MitoTracker Deep Red fluorescence 649 
intensity data were collected using ex. 640 nm, em. 660±10 nm. 650 
 651 
Mammalian Mitochondrial Isolation 652 
Cells were cultured on a 100 mm or 150 mm plate. For experiments where mitochondria were depleted 653 
of NAD+, the media was changed the day before collection and the cells were treated with 100 nM FK866 654 
for 18-24 hours. Cells were collected by trypsinization. Mitochondria were isolated by homogenizing cells 655 
in 2 mL of mitochondrial isolation buffer (210 mM Mannitol, 70 mM Sucrose, 10 mM HEPES, 1 mM 656 
EGTA, 0.25% fatty acid free BSA; adjust pH to 7.2 with KOH) using a dounce homogenizer (1200 rpm for 657 
20 strokes). Mitochondria were collected by differential centrifugation. Cell debris was spun down at 800 658 
g for 10 min and supernatant was transferred to a new tube. This was repeated until no cell debris pellet 659 
was present. Next the supernatant was spun at 11,000 g for 15 min. The mitochondrial pellet was 660 
resuspended in 50-200 μL BSA-free mitochondrial isolation buffer. 661 
 662 
Mammalian mitochondrial NAD+ uptake 663 
To measure mitochondrial NAD+ uptake, isolated mitochondria (50-200 μg) were resuspended in MiR05 664 
containing 5 mM malate and 10 mM pyruvate along with NAD+ (1 mM) in a 1.5 mL Eppendorf tube. The 665 
reaction was agitated at 900 rpm and the tube was briefly opened every 10 min to allow for re-666 
oxygenation. Mitochondria were pelleted by centrifugation (14,000g for 2 min). The mitochondrial pellet 667 
was washed 2 times with ice-cold Mitochondrial Isolation Buffer before extracting in ice-cold 0.6 N 668 
perchloric acid for biochemical measurements of mitochondria NAD+ content. 669 
 670 
Labeled NaR and Metabolomics 671 
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For the tracer studies, cells were treated with double-isotope labeled 0.1 mM nicotinic acid riboside (NaR, 672 
double labeled with a 13C label on the pyridine carboxyl group and a deuterium label on the ribose 673 
moiety) for 7 hrs in complete Iscove's Modified Dulbecco's culture medium supplemented with 10% fetal 674 
bovine serum and 1x penicillin/streptomycin and 50 µg/mL uridine before extracting. The cells were then 675 
rapidly harvested using trypsin and media containing the label and were washed with ice-cold isolation 676 
buffer. Either cells or subsequently isolated mitochondria were collected for analysis. 677 
Metabolites were extracted from pelleted mitochondria and whole cells using -80°C 80:20 678 
methanol:water. Whole cell and mitochondria extracts were analyzed by liquid chromatography coupled 679 
to a mass spectrometer (LC-MS). The LC–MS method employed hydrophilic interaction chromatography 680 
(HILIC) coupled to the Q Exactive PLUS mass spectrometer (Thermo Scientific) 36. The LC separation 681 
was performed on a XBridge BEH Amide column (150 mm 3 2.1 mm, 2.5 mm particle size, Waters, 682 
Milford, MA). Solvent A is 95%: 5% H2O: acetonitrile with 20 mM ammonium bicarbonate, and solvent B 683 
is acetonitrile. The gradient was 0 min, 85% B; 2 min, 85% B; 3 min, 80% B; 5 min, 80% B; 6 min, 75% 684 
B; 7 min, 75% B; 8 min, 70% B; 9 min, 70% B; 10 min, 50% B; 12 min, 50% B; 13 min, 25% B; 16 min, 685 
25% B; 18 min, 0% B; 23 min, 0% B; 24 min, 85% B; 30 min, 85% B. Other LC parameters are: flow rate 686 
150 ml/min, column temperature 25°C, injection volume 10 mL and the autosampler temperature was 687 
5°C. The mass spectrometer was operated in both negative and positive ion mode for the detection of 688 
metabolites. Other MS parameters are: resolution of 140,000 at m/z 200, automatic gain control (AGC) 689 
target at 3e6, maximum injection time of 30 ms and scan range of m/z 75-1000. Raw LC/MS data were 690 
converted to mzXML format using the command line “msconvert” utility 37.  Data were analyzed via 691 
MAVEN v3.1 software, and all isotope labeling patterns were corrected for natural 13C abundance using 692 
AccuCor 38. To determine metabolites that were significantly changed, the fold change of metabolites 693 
was analyzed with multiple t-tests and a false discovery rate (FDR) was calculated using the two-stage 694 
step-up method of Benjamini, Krieger, and Yekutieli) with a desired FDR of 1%. A volcano plot was 695 
generated using Prism 8.0 comparing the -log(adjusted P value) to fold change. A heat map was 696 
generated using MetaboAnalyst 3.0 39. To generate the heat map, the samples were normalized by the 697 
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median and the data was log transformed. A hierarchical clustering heat map was produced using a 698 
Pearson correlation to determine distance and Ward’s method for clustering analysis. T-test/ANOVA was 699 
used to determine Top 30 metabolite changes.  700 
 701 
Generation of stably transfected HEK293 cells 702 
Parental HEK293 cells were cultivated in DMEM (high glucose) supplemented with 10 % (v/v) fetal calf 703 
serum (FCS), 2 mM glutamine, 1 mM sodium pyruvate 100 U/mL penicillin and 100 µg/mL streptomycin. 704 
One day after transfection of 106 parental HEK293 cells in a 6-well plate with 1 µg plasmid encoding C-705 
terminally FLAG-HA-tagged carriers using X-tremeGENE 9 transfection reagent (Merck Sigma XTG9-706 
RO), one fifth of the cells were distributed onto a 10 cm dish and grown for ten days in complete DMEM 707 
supplemented with 550 µg/mL G418 whilst replacing the medium every other day. A total of 350 708 
surviving cells were seeded on a 10 cm dish for a first round of clonal selection. Subsequently, cell 709 
clones were transferred into a 24 well plate and further expanded. Cells stably expressing the transgene 710 
were identified by FLAG-immunoblot analysis and subjected to another round of clonal selection. 711 
 712 
Poly-ADP-ribose assisted detection of mitochondrial NAD+ 713 
Parental HEK293 cells and stably transfected HEK293 cells expressing Arabidopsis thaliana NDT2 714 
(AtNDT2), human SLC25A32 and human SLC25A51 were grown in a 6-well plate and transfected with 1 715 
µg plasmid encoding a mitochondrially targeted fusion construct composed of EGFP and the catalytic 716 
domain of PARP1 (mitoPARP1cd) using X-tremeGENE 9 transfection reagent. Cells transfected with the 717 
same construct lacking the PARP1cd portion (mitoEGFP) served as control. Thirty hours post 718 
transfection, cells were washed with 1 mL PBS prior to adding 130 µL lysis buffer (20 mM TrisHCl [pH 719 
7.4], 150 mM NaCl, 1% (v/v) SDS, 1 mM EDTA, 1 mM 3-aminobenzamide). After 10 times passaging of 720 
the lysates through a 23-gaugle needle and determination of protein concentration using BCA assay 721 
(ThermoFisher, #23225), 50 µg of lysate were separated by reducing SDS-polyacrylamide gel 722 
electrophoresis in a 7% and 10% gel and subjected to immunoblotting using anti-PAR, anti-FLAG, anti-723 
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GFP, and anti-β-tubulin antibodies followed by incubation with HRP-conjugated goat anti-mouse 724 
secondary antibody. Overnight incubation at 4°C was used for primary antibodies and 1 h incubation at 725 
room temperature for the secondary antibody. HRP-detection was performed using Super Signal West 726 
Dura Extended Duration Substrate (ThermoFisher, #34075) and a ChemiDoc XRS+ imaging system 727 
(Bio-Rad). 728 
 729 
Generation of Yeast Strains  730 
The ndt2∆::KanMX targeted deletion strain in BY4742 (MATα; his3∆1; leu2∆0; lys2∆0; ura3∆0) 731 
background was purchased from the Yeast Knockout Collection through GE (#YSC6272-201917555) 732 
and confirmed via genomic PCR. The double ndt1∆ ndt2∆ knockout strain was generated by additional 733 
cassette replacement of NDT1 with the HygMX cassette from pAG32. pRS415 or pRS415-based 734 
plasmids containing sc. NDT1, SLC25A51, or SLC25A52 were transformed using the LiAc method 40, 735 
selected for and maintained in SC-Leu media. 736 
 737 
Yeast Mitochondrial Isolation 738 
Mitochondria were isolated as previously described 41.  Briefly, mitochondria were grown in 500 mL YPR 739 
(yeast extract, peptone, 2% raffinose) until the culture reached exponential phase.  Raffinose was used 740 
as a carbon source instead of dextrose to promote respiration 42.These cultures were pelleted, washed 741 
and resuspended in zymolyase buffer (1.2M sortbitol, 20 mM potassium phosphate, pH 7.4).  The cell 742 
suspension was treated with zymolyase at 1 unit per mL of the original culture and shaken at 80 rpm at 743 
30˚C for 30 minutes.  After zymolyase treatment the spheroplasts were kept on ice.  The spheroplasts 744 
were pelleted, washed and resuspended in homogenization buffer (0.6M sorbitol, 10 mM Tris-HCl, pH 745 
7.4, 1 mM ethylenediaminetetraacetic acid (EDTA) 0.2% w/v BSA and protease inhibitors at 2X).  For 746 
mass-spectrometry analysis, BSA was omitted. The suspension was homogenized using 15 strokes of a 747 
10 mL dounce homogenizer.  The mitochondria were then isolated from the lysate using differential 748 
centrifugation.  The mitochondria were stored on ice and in buffer containing sorbitol to preserve the 749 
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osmolarity of the organelles (Homogenization Buffer).  Isolated mitochondria were used within 3 hours of 750 
isolation. 751 
 752 
Uptake of 3H-NAD+ in Isolated Yeast Mitochondria 753 
Uptake was performed as previously described 43. Isolated mitochondria (3 mg for 3 timepoints) were 754 
pelleted at 12,000 x g for 10 minutes at 4˚C. Protein concentrations were measured using A280 755 
spectrophotometry.  Mitochondrial pellets were maintained in sorbitol buffer until immediately before use.  756 
Pellets were resuspended in 50 µL suspension Buffer (120 mM KCl, 5 mM KH2PO4, 1 mM EGTA, 3 mM 757 
HEPES pH 7.4, pH to 7.4 with KOH). The reaction was initiated by addition of 100 µL of respiration buffer 758 
(120 mM KCl, 5 mM KH2PO4, 1 mM EGTA, 3 mM HEPES pH 6.8) that included 1.5X substrate mix (1.5 759 
mM ADP, 1.5 mM ATP, 30 mM succinate, 150 μM malate, 150 μM–1500 µM NAD+ as indicated, pH to 760 
6.8 with KOH). Reaction buffer also included 0.3–3 nmol of 3H-NAD+, depending on relative NAD+ 761 
concentration to maintain the ratio when varying the concentration of substrate. For competition assays, 762 
0.3 nmol 3H-NAD+ was used. 3H-NAD+ was purchased from Moravek, Inc (1 mCi/mL). The total 1X 763 
reaction volume was 150 µL, yielding three 50 µL samples for 1, 3 and 30 min timepoints. Each timepoint 764 
was filtered through a 0.22 μm MCE filter using vacuum filtration and then washed with 5 mL suspension 765 
buffer. Washed filters were placed in a 7 mL scintillation vial and dissolved in 5 mL Filtron-X scintillation 766 
fluid. Scintillation vials were analyzed using an LSC6500 liquid scintillation counter at 1 min per sample.  767 
Background signal from equivalent amounts of 3H-NAD+ incubated without mitochondria was subtracted. 768 
For calculating rates, mean background signal from the DKO strain was subtracted.  769 
 770 
Quantitation of SLC25A51 abundance in yeast samples 771 
Wild-type, double-knockout (∆ndt1 ∆ndt2) and pRS415-TEF SLC25A51; ∆ndt1 ∆ndt2 strains were grown 772 
in triplicate in 250 mL YPR (Yeast extract, peptone, 2% raffinose) to mid-exponential phase at 30°C, 225 773 
rpm.  OD600 was used to estimate the cell concentrations of each culture so that 9 x 10
9 cells were used 774 
for each isolation. Mitochondria were isolated in the absence of BSA. After determining the yield of each 775 
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mitochondrial preparation, 10 μg of mitochondria per sample were pelleted at 10,000 x g for 15 minutes 776 
at 4°C. The mitochondrial pellet was lysed in 20 µL of 20 mM Tris pH 7.4, 200 mM NaCl, 20 mM C12M 777 
for 30 min at 4C. The lysate was centrifuged at 10,000 x g for 30 min at 4°C and supernatant was 778 
immediately placed in 20 µL 2X Laemmli Buffer and boiled at 95C for 5 min. The samples were resolved 779 
in a 10% Bis-Tris gel at 100V for 20 minutes and stained with Imperial Stain. Gel sections between 25 780 
kDa and 37 kDa were excised with a clean razorblade and treated with 50% ethanol, 50 mM ammonium 781 
bicarbonate for 30 min at RT. Gel cubes were then reduced and subjected to in-gel digest with trypsin. 782 
Peptide samples were extracted in acetonitrile and desalted before analysis on a Dionex LC and Orbitrap 783 
Fusion 1 for LC MS/MS with a two-hour run time. Integrated peak intensities were mapped onto a known 784 
meta dataset of absolute protein abundances 33 to interpolate an estimate of SLC25A51 abundance per 785 
mg of mitochondria. Selection of proteins used to generate the standard curve were uniquely 786 
mitochondrially localized, had consistent abundance across all experimental conditions, and had 787 
confirmed molecular weights between 25 and 37 kDa. Using the standard curve, the amount of 788 
SLC25A51 expressed was estimated to be ~3000 molecules per cell. Calculated concentration of 789 
SLC25A51 in each uptake reaction was ~280 nM ± 40 nM SLC25A51 or ~500 ng ± 70 ng SLC25A51 per 790 
mg of mitochondria. 791 
 792 
Immunofluorescence and Imaging 793 
Approximately thirty hours following transient transfected of either pCMV-Flag-HA-SLC25A51 or pCMV-794 
Flag-HA-SLC25A52, HeLa cells seeded on coverslips were fixed using 4% paraformaldehyde (Electron 795 
Microscopy Sciences #15710)/PBS for 15 minutes at room temperature. Fixed cells were then washed in 796 
PBS, blocked, and permeabilized for 1 hour at room temperature in 5% normal goat serum/0.3% Triton 797 
X-100/PBS. Primary antibodies were diluted and incubated with cells overnight at 4ºC in 1% BSA/0.3% 798 
Triton X-100/PBS. Rabbit anti-Flag (Cell Signaling Technologies #14793, 1:500); mouse anti-MTC02 799 
(Abcam ab79479, 1:40). After washing, secondary antibodies were similarly diluted and incubated with 800 
cells for 1 hour at room temperature. Goat anti-Mouse IgG - Alexa Fluor 488 (Invitrogen A-11001, 801 
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1:1000); Goat anti-Rabbit IgG - Alexa Fluor 568 (Invitrogen A-11036, 1:1000). Following 3X PBS washes, 802 
cells were mounted with Vectashield Hardset w/ DAPI (Vector Labs, H-100). 0.11 µm optical slices were 803 
imaged using a Yokogawa W2 spinning disk confocal setup that includes 100mW 488 nm and 565 nm 804 
lasers, a 100X Olympus objective, and a Photonics Prime 95B sCMOS camera.  805 
 806 
Mitochondrial Volumetric Analyses 807 
For analyses of mitochondrial volume per cell, a z-stack series comprised of 0.11 µm optical slices that 808 
comprehensively covered the full depth of a single cell was captured and imported into Bitplain Imaris 809 
x64 (v.8.4.1) for assembly. Data for over 30 individual w per experimental condition were blindly collected 810 
and analyzed. Power analysis (alpha 0.05, beta 0.8) indicated that a sample size of 26 cells would be 811 
sufficient to observe differences with this confidence. Surfaces analysis was performed for each cell; 812 
surface detail was set to 0.1 µm. For thresholding, background subtraction (local contrast) was 813 
performed using a spherical diameter of 0.2 µm surrounding the identified surfaces.  A volume filter was 814 
applied to analyze objects above 0.0184 µm3. Data were collected for cumulative volume per cell, 815 
number of disconnected puncta components per cell, and median volume of each disconnected unit. 816 
Data were analyzed for statistical significance between conditions using GraphPad Prism v8.2.0.  817 
   818 
Statistics and Reproducibility 819 
All results are presented as mean ± standard error of the mean as indicated. Statistical analyses were 820 
performed using Prism 8.0 (Graph Pad Software) and Microsoft Excel. Where appropriate, statistical 821 
analyses were performed using an unpaired, two-tailed t-test (for comparison of two groups), one-way 822 
ANOVA (for comparison of three or more groups), or two-way ANOVA (for grouped analysis). Multiple 823 
comparisons analysis was performed using Dunnett’s, Tukey’s, or Sidak’s methods (method was selected based on 824 
the recommendation of Prism 8.0 for a given comparison). P values less than 0.05 were considered significant. 825 
All experiments are represented by multiple biological replicates or independent experiments. The 826 
number of replicates per experiment are indicated in the legends.  827 
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For data presented in Fig. 2h, the data for shControl are representative of 2 independent 828 
experiments and the data for shSLC25A51 are representative of 4 independent experiments. Over 30 829 
cells were analyzed per condition.  830 
For data presented in Extended Data Fig. 1e the experiment was repeated 2 independent times; 831 
for Extended Data Fig. 1h, NDT1 and vector experiments were repeated 24 times and the experiment for 832 
each transporter was repeated 4 times; for Extended Data Fig. 1i the experiment was repeated 4 833 
independent times and over 20 cells were analyzed each time; for Extended Data Fig. 4a, the experiment 834 
was repeated 3 times and 9 distinct colonies were tested; for Extended Data Fig. 4b, the experiment was 835 
repeated over 10 times with over 10 transformations and 3 colonies were tested for each transformation. 836 
This experiment was regularly repeated throughout use of the strain to validate that its growth phenotype 837 
was as expected. For Extended Data Fig. 4c, this experiment was repeated over 10 times; including over 838 
10 transformation with 3 colonies tested per transformation. This experiment was regularly repeated 839 
throughout use of the strain to validate that no compensatory mutations had been created. For Extended 840 
Data Fig. 4d, this experiment was repeated 2 independent times. For Extended Data Fig. 4e, this 841 
experiment was performed once with technical triplicates. 842 
 843 
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Extended Data Figure Legends 876 
Extended Data Figure 1. SLC25A51 is a mitochondrial protein that affects cellular 877 
NAD+ distribution, proliferation, and metabolome profiles. 878 
qPCR quantification of SLC25A51 mRNA expression in a, HEK293T (n=3) and b, HeLa cells (n=3) 879 
expressing shRNA targeting SLC25A51.  NAD+ content of c, isolated mitochondria (n=3) and d, whole 880 
cell lysates (n=3) from HeLa cells with stable shRNA knockdown of SLC25A51 (KD) and non-targeting 881 
control (Ctrl). e, Western blot confirming shRNA targeting murine Slc25a51 reduces SLC25A51 protein 882 
expression in cells transfected with cDNA encoding SLC25A51-FLAG. f, Mitochondrial free NAD+ levels 883 
in mouse embryonic stem cells expressing shRNA against Slc25a51 and non-targeting shRNA (shFF2), 884 
as measured with the mitochondrial cpVenus NAD+ biosensor (n=3). g, qPCR quantification of 885 
SLC25A51 mRNA expression in HeLa cells transfected with siRNA targeting SLC25A51 (n=3). h, 886 
Western blot confirming protein expression of Flag-tagged mitochondrial carriers. Controls include stable 887 
expression of the NAD+ biosensor (sensor) and anti-Tubulin for loading. i, Immunofluorescent detection 888 
of SLC25A51 and SLC25A52 subcellular localization. Cells were transiently transfected with cDNA 889 
encoding Flag-HA-tagged SLC25A51 or SLC25A52 and probed with anti-Flag and the mitochondrial 890 
marker, anti-MTC02. Scale bar: 10 µM, 2 µM on inset. Inset represents zoomed view of Flag localization 891 
and mitochondria. Proliferation of j, HAP1 SLC25A51 KO (n=8), k, HEK293T SLC25A51 shRNA-892 
knockdown (n=8) l, HeLa SLC25A51 shRNA-knockdown cells (n=8) and their respective controls. 893 
Proliferation was measured by CyQuant, a fluorescent DNA dye, at 0h and 96h after plating and 894 
expressed as fold change. qPCR quantification of SLC25A52 mRNA expression in m, HAP1 SLC25A51 895 
KO, n, HEK293T SLC25A51 shRNA-knockdown and o, HeLa SLC25A51 shRNA-knockdown cells (n=3). 896 
p, Western blot of whole cell protein lysates from HAP1 wildtype (WT) and SLC25A51 knockout (KO) 897 
cells confirming SLC25A51 loss. Loading control is total protein measured by Revert 700 Total Protein. 898 
Heat map of top 30 q, mitochondrial and r, whole cell metabolites that differ between HAP1 wildtype and 899 
SLC25A51 KO cells (n=3). Data represented as mean ± SEM. P values were determined by unpaired, 900 
two-tailed Student’s t-test (for two groups) or one-way ANOVA with multiple comparisons analysis using 901 
Dunnett’s method (for groups of three or more). *P<0.05, and ***P<0.001 vs control or WT (exact P 902 
values are provided in the source data). 903 
 904 
Extended Data Figure 2. NAD+ and SLC25A51 affect oxidative phosphorylation. 905 
a, Respiration of isolated mitochondria from HEK293T cells treated with either vehicle (Veh) or the 906 
NAMPT inhibitor FK866 to deplete mitochondrial NAD+. Mitochondria were treated with pyruvate and 907 
malate (state 2), then ADP was added to induce state 3 respiration. 1 mM NAD+ was added to test the 908 
ability of exogenous NAD+ to rescue respiration in the setting of mitochondria NAD+ depletion (Trace is 909 
representative of n=4 independent experiments). P values were determined by two-way ANOVA with 910 
multiple comparisons analysis using the Sidak method. b, Oxygen consumption rate (OCR) was 911 
measured in SLC25A51 shRNA knockdown (KD) and control (Ctrl) HeLa cells using a Seahorse XF96e. 912 
Basal OCR was measured prior to the addition of treatments and maximal respiration was measured 913 
after the sequential addition of oligomycin (Oligo, ATP synthase inhibitor) and FCCP (uncoupler). 914 
Rotenone (Rot) and Antimycin A (AA) were added as a control to completely block mitochondrial oxygen 915 
consumption (n=6). c, Respiration of isolated mitochondria from SLC25A51 knockdown HEK293T cells. 916 
Mitochondria were treated with pyruvate/malate (state 2), and then ADP was added to induce state 3 917 
respiration. Oligomycin was added to block ATP synthase-mediated respiration (n=3 independent 918 
experiments). d, Mitochondria were isolated from HEK293T control, SLC25A51 shRNA knockdown cells, 919 
and controls treated with FK866 to deplete mitochondrial NAD+. Mitochondrial oxygen consumption rate 920 
was measured after treatment with pyruvate/malate (state 2), ADP (state 3), and 1 mM NAD+ (n=4 921 
independent experiments). e, Mean volume per mitochondrial unit and f, number of distinct mitochondria 922 
per cell quantified from confocal image reconstructions of mitochondrial voxels in SLC25A51 shRNA 923 
knockdown (n=31 cells) and control (n=32 cells) HeLa cells. Data represented as mean ± SEM. P values 924 
were determined by unpaired, two-tailed Student’s t-test. *P<0.05, **P<0.01, and ***P<0.001 vs vehicle 925 
or control; ###P<0.001 vs state 3 (exact P values are provided in the source data). 926 
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 927 
Extended Data Figure 3. Intact NAD+, but not nicotinamide or nicotinamide mononucleotide 928 
contributes to the mitochondrial NAD+ pool. 929 
 a, Mitochondrial NAD+ content was measured in isolated mitochondria from a, HeLa control (Ctrl) cells, 930 
cells treated with FK866 (Ctrl+FK), and SLC25A51 shRNA-knockdown (KD) cells. NAD+ content of 931 
isolated mitochondria was determined before (untreated) and after a 40-min incubation with 1 mM NAD+ 932 
(n=3 independent experiments). b, NAD+ levels in HEK293T mitochondria incubated with 1 mM 933 
nicotinamide (NAM), 1 mM nicotinamide mononucleotide (NMN), or 1 mM NAD+ (n=3 independent 934 
experiments). c, NAD+ uptake in NAD+-depleted mitochondria isolated from HEK293T cells incubated 935 
with NAD+ ± 2 mM NAM or 2mM NMN (n=4 independent experiments). d, Fractional labeling of 936 
mitochondrial NAD+ in HAP1 cells treated with isotopically double labeled NaR (n=3 biological 937 
independent replicates). Data represented as mean ± SEM. P values were determined by unpaired, two-938 
tailed Student’s t-test (for two groups) or one-way ANOVA with multiple comparisons analysis using 939 
Dunnett’s or Tukey’s method (for groups of three or more). *P<0.05 and ***P<0.001 vs untreated, vehicle, 940 
and wildtype M+0; #P<0.05 vs wildtype M+1. 941 
 942 
Extended Data Figure 4. Generation and validation of yeast strains for testing mitochondrial NAD+ 943 
transport. 944 
a, PCR genotyping to confirm double knockout gene deletion in BY4727 S. Cerevisiae via antibiotic-945 
resistance cassette replacement at the NDT1 and NDT2 loci. b, c, Deletion of the mitochondrial NAD+ 946 
carriers NDT1 and NDT2 in DKO strain phenocopied previously described growth defects on non-947 
fermentative media (YP, 3% glycerol media)2, which was rescued by plasmid expression of NDT1 d, 948 
Western blot confirmed enrichment of mitochondrial markers (MTC02 and COXIV) and absence of 949 
cytoplasmic proteins (actin) or ER (SC2) in isolated mitochondria from yeast. e, RT-PCR confirmed 950 
ectopic expression from pRS415-SLC25A51 and pRS415-SLC25A52 in DKO strains.  951 
 952 
Extended Data Figure 5. Kinetics and selectivity of NAD+ transport by human SLC25A51 953 
expressed in yeast mitochondria. 954 
a, Co-incubation with excess unlabeled NAD+ (n=5 independent experiments for 1mM NAD+) b, 955 
supraphysiological levels of NMN (100 µM, n=4 independent experiments; 500 µM, n=5 independent 956 
experiments), or c, NADH (n=3 independent experiments) with 3H-NAD+ to measure uptake competition 957 
in mitochondria from DKO yeast expressing SLC25A51. d, Proportional relationship between integrated 958 
peak intensities from mass spectrometry of mitochondrial samples compared to a known meta dataset of 959 
absolute protein abundances; used to quantitate SLC25A51 abundance in yeast samples. e, Uptake 960 
measured with indicated NAD+ concentrations; calculated from specific activity (n=3 independent 961 
experiments, mean ± SEM).  f, Lineweaver-Burk plot based on a non-linear fit with datapoints overlaid 962 
(n=3 independent experiments). P values were determined by two-way ANOVA with multiple 963 
comparisons analysis using Sidak’s method. *P<0.05 and **P<0.01 vs 100 µM cold NAD+. 964 
 965 
Extended Data Table 1. Essential mitochondrial solute carrier family 25 genes determined by 966 
genome-wide CRISPR/Cas9 screens examining cellular viability. Table includes essential gene 967 
name, number of cell lines in which gene is essential, number of cell lines tested, corresponding citation 968 
of study utilizing genome-wide CRISPR/Cas9 screens to determine essential genes, 969 
annotation (Uniprot), and tissue expression profile (Human Protein Atlas20). #SLC25A51 was not tested in 970 
Hart et al. Cell, 2015. 971 
 972 
Extended Data Table 2. Initial NAD+ Uptake Rates Calculated from Specific Activity in Isolated 973 
Mitochondria. P values were determined by unpaired, two-tailed Student’s t-test. 974 
 975 
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